134 related articles for article (PubMed ID: 38671586)
1. Erratum to: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Br J Haematol; 2024 Jun; 204(6):2520. PubMed ID: 38671586
[No Abstract] [Full Text] [Related]
2. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Wilcox LJ; Barrett PH; Huff MW
J Lipid Res; 1999 Jun; 40(6):1078-89. PubMed ID: 10357840
[TBL] [Abstract][Full Text] [Related]
4. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.
Maqbool MG; Tam CS; Morison IM; Simpson D; Mollee P; Schneider H; Chan H; Juneja S; Harvey Y; Nath L; Hissaria P; Prince HM; Wordsworth H; Opat S; Talaulikar D
Pathology; 2020 Feb; 52(2):167-178. PubMed ID: 31902622
[TBL] [Abstract][Full Text] [Related]
5. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Yada T; Nakata M; Shiraishi T; Kakei M
Br J Pharmacol; 1999 Mar; 126(5):1205-13. PubMed ID: 10205010
[TBL] [Abstract][Full Text] [Related]
6. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
7. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
11. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
Gouni-Berthold I; Berthold HK; Gylling H; Hallikainen M; Giannakidou E; Stier S; Ko Y; Patel D; Soutar AK; Seedorf U; Mantzoros CS; Plat J; Krone W
Atherosclerosis; 2008 May; 198(1):198-207. PubMed ID: 17980884
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
13. [Waldenström macroglobulinaemia].
Simon L; Leblond V
Rev Prat; 2018 Sep; 68(7):797-802. PubMed ID: 30869336
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP; Correa JG; Battram AM; Osuna M; Rivas-Delgado A; Rodríguez-Lobato LG; Cardús O; Tovar N; Cibeira MT; Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C
Br J Haematol; 2023 Jan; 200(2):187-196. PubMed ID: 36210485
[TBL] [Abstract][Full Text] [Related]
15. Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemia.
Durot E; Delmer A
Br J Haematol; 2023 Jun; 201(5):809-810. PubMed ID: 36794868
[TBL] [Abstract][Full Text] [Related]
16. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
Castillo JJ; Advani RH; Branagan AR; Buske C; Dimopoulos MA; D'Sa S; Kersten MJ; Leblond V; Minnema MC; Owen RG; Palomba ML; Talaulikar D; Tedeschi A; Trotman J; Varettoni M; Vos JM; Treon SP; Kastritis E
Lancet Haematol; 2020 Nov; 7(11):e827-e837. PubMed ID: 33091356
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells.
Mark M; Muller P; Maier R; Eisele B
J Lipid Res; 1996 Jan; 37(1):148-58. PubMed ID: 8820110
[TBL] [Abstract][Full Text] [Related]
18. Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection.
Liu L; Zhang R; Zhao JJ; Rogers JD; Hsieh JY; Fang W; Matuszewski BK; Dobrinska MR
J Pharm Biomed Anal; 2003 Apr; 32(1):107-23. PubMed ID: 12852453
[TBL] [Abstract][Full Text] [Related]
19. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor).
Horsmans Y; Desager JP; Harvengt C
Pharmacol Toxicol; 1990 Oct; 67(4):336-9. PubMed ID: 2077527
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner.
Ogura T; Tanaka Y; Nakata T; Namikawa T; Kataoka H; Ohtsubo Y
J Toxicol Sci; 2007 Feb; 32(1):57-67. PubMed ID: 17327694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
